Publication Name	World Journal of Gastroenterology
Manuscript ID	5922
Country	United States

Received	2013-09-28 20:48
Peer-Review Started	2013-09-30 10:54
To Make the First Decision	2013-11-04 19:42
Return for Revision	2013-11-05 09:07
Revised	2013-11-08 03:26
Second Decision	2014-01-06 18:33
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-01-06 18:50
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-01-20 09:55
Publish the Manuscript Online	2014-02-20 19:40

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Suneeta Krishnareddy and Arun Swaminath
Funding Agency and Grant Number
Corresponding Author	Arun Swaminath, MD, Assistant Professor of Medicine, Mount Sinai School of Medicine, Columbia University Medical Center, 1425 Madison Avenue 622 West 168th Street, New York, NY 10029, United States. aswaminath@NSHS.edu
Key Words	Inflammatory bowel disease; Emerging therapies; Vedolizumab; Ustekinumab; Tofacitinib
Core Tip	In this paper we critically review recently published literature about these novel therapies, which have been the results of extensive research identifying molecular targets. Several agents have been tested and show promising data, but we focus on vedolizumab, a monoclonal antibody against the ?4?7 integrin on lymphocytes, ustekinumab, a monoclonal antibody against the p40 subunit of interleukin-12 and interleukin-23, and tofacitinib, an orally administered small molecule targeting Janus-activated kinase. These three agents are most likely to find their way soon to the market and offer significant therapeutic advantages for the management of Crohn’s disease and ulcerative colitis.
Publish Date	2014-02-20 19:40
Citation	Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146
URL	http://www.wjgnet.com/1007-9327/full/v20/i5/1139.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i5.1139

Full Article (PDF)	WJG-20-1139.pdf
Full Article (Word)	WJG-20-1139.doc
Manuscript File	5922-Review.doc
Answering Reviewers	5922-Answering reviewers.pdf
Copyright License Agreement	5922-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5922-Language certificate.pdf
Peer-review Report	5922-Peer reviews.pdf
Scientific Editor Work List	5922-Scientific editor work list.doc